Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Our H2 2025 Top Ideas
09:00am, Wednesday, 10'th Sep 2025
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now
US FDA to step up enforcement of pharma ads, sends enforcement letters
07:12pm, Tuesday, 09'th Sep 2025
The U.S. Food and Drug Administration will send out around 100 cease-and-desist enforcement notices and thousands of letters warning pharmaceutical companies that direct-to-consumer ads must comply wi
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
12:36pm, Tuesday, 09'th Sep 2025
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
12:26pm, Tuesday, 09'th Sep 2025
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Eli Lilly launches AI platform for drug discovery
10:39am, Tuesday, 09'th Sep 2025
Eli Lilly and Co (NYSE:LLY) has introduced Lilly TuneLab, an artificial intelligence and machine learning platform designed to support early-stage biotechnology companies in drug discovery. The system
Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors Nearly four in five Amer
Eli Lilly launches platform for AI-enabled drug discovery
07:09am, Tuesday, 09'th Sep 2025
Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of Lilly's
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines New offering expands Lilly Catalyze360's support for early-stage drug development INDIANAPOLI
Eli Lilly (LLY) Laps the Stock Market: Here's Why
08:37pm, Monday, 08'th Sep 2025
Eli Lilly (LLY) concluded the recent trading session at $738.17, signifying a +1.51% move from its prior day's close.
Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
12:34pm, Monday, 08'th Sep 2025
Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Jacob Van Naarden - Executive VP & President of Lilly Oncol
Lilly's blood cancer drug meets main goal in late-stage study
06:57am, Monday, 08'th Sep 2025
Eli Lilly said on Monday its blood cancer treatment Jaypirca met the main goal in a late-stage study in patients who have not received prior treatment.
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine
Top 50 High-Quality Dividend Stocks For September 2025
12:18pm, Saturday, 06'th Sep 2025
I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 sto
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
01:10pm, Friday, 05'th Sep 2025
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment t
